IRIS
ALTAVILLA, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 10.929
NA - Nord America 9.523
AS - Asia 5.015
SA - Sud America 1.697
AF - Africa 136
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 7
Totale 27.319
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.360
RU - Federazione Russa 5.153
SG - Singapore 2.191
BR - Brasile 1.497
CN - Cina 1.427
IE - Irlanda 1.302
SE - Svezia 1.241
IT - Italia 856
HK - Hong Kong 539
DE - Germania 504
UA - Ucraina 482
GB - Regno Unito 326
FR - Francia 315
FI - Finlandia 265
VN - Vietnam 247
PL - Polonia 194
IN - India 142
BD - Bangladesh 86
CA - Canada 68
BE - Belgio 65
TR - Turchia 60
AR - Argentina 54
MX - Messico 52
IQ - Iraq 47
ZA - Sudafrica 41
EC - Ecuador 40
ID - Indonesia 35
NL - Olanda 35
CO - Colombia 34
ES - Italia 34
AT - Austria 32
UZ - Uzbekistan 28
JP - Giappone 24
MA - Marocco 24
CZ - Repubblica Ceca 23
VE - Venezuela 23
AE - Emirati Arabi Uniti 17
PK - Pakistan 17
IR - Iran 15
SA - Arabia Saudita 15
AZ - Azerbaigian 14
BO - Bolivia 13
AL - Albania 12
KE - Kenya 12
CL - Cile 11
LT - Lituania 11
TN - Tunisia 11
CH - Svizzera 10
CI - Costa d'Avorio 10
JO - Giordania 10
PH - Filippine 10
PY - Paraguay 10
AU - Australia 9
EG - Egitto 9
IL - Israele 9
JM - Giamaica 9
KG - Kirghizistan 9
DO - Repubblica Dominicana 8
GR - Grecia 8
KZ - Kazakistan 8
NP - Nepal 8
OM - Oman 8
RS - Serbia 8
PE - Perù 7
PS - Palestinian Territory 7
NO - Norvegia 6
UY - Uruguay 6
AM - Armenia 5
AO - Angola 5
BA - Bosnia-Erzegovina 5
BG - Bulgaria 5
GE - Georgia 5
LB - Libano 5
NI - Nicaragua 5
PA - Panama 5
RO - Romania 5
BY - Bielorussia 4
CR - Costa Rica 4
DZ - Algeria 4
ET - Etiopia 4
HN - Honduras 4
KR - Corea 4
KW - Kuwait 4
LV - Lettonia 4
SK - Slovacchia (Repubblica Slovacca) 4
SN - Senegal 4
SV - El Salvador 4
TH - Thailandia 4
DK - Danimarca 3
HR - Croazia 3
HU - Ungheria 3
MY - Malesia 3
NZ - Nuova Zelanda 3
PT - Portogallo 3
XK - ???statistics.table.value.countryCode.XK??? 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BW - Botswana 2
EE - Estonia 2
EU - Europa 2
GA - Gabon 2
Totale 27.287
Salva come PNG Salva come JPEG
Città #
Moscow 1.476
Ashburn 1.339
Dublin 1.302
Singapore 1.173
Chandler 990
Jacksonville 943
Dallas 916
Nyköping 691
Hong Kong 534
San Jose 514
Beijing 488
The Dalles 294
Dearborn 251
Los Angeles 246
Ann Arbor 244
Princeton 218
Cambridge 199
Medford 199
Warsaw 187
Lauterbourg 183
New York 163
Messina 160
Des Moines 153
Boardman 130
Munich 121
São Paulo 116
Lancaster 110
Buffalo 89
Tianjin 82
Jinan 78
Ho Chi Minh City 75
Council Bluffs 69
Woodbridge 67
Brussels 62
Orem 52
Shenyang 52
Guangzhou 51
Hanoi 51
Redondo Beach 51
Rio de Janeiro 51
Santa Clara 51
Turku 50
Wilmington 48
San Mateo 45
Frankfurt am Main 42
Houston 40
Nanjing 36
Belo Horizonte 35
Chicago 32
Rome 30
Catania 29
Hyderabad 29
Milan 28
Montreal 28
Brooklyn 27
Hebei 27
Seattle 27
Vienna 27
Atlanta 26
Brasília 26
Pune 26
San Francisco 26
Tashkent 26
Zhengzhou 26
Jakarta 23
London 23
Tokyo 23
Washington 22
Baghdad 21
Chennai 21
Denver 21
Curitiba 20
Haikou 20
Helsinki 20
Nanchang 20
Porto Alegre 20
Düsseldorf 19
Mumbai 19
Nuremberg 19
Stockholm 19
Istanbul 18
Johannesburg 18
Shanghai 18
Dong Ket 17
Ningbo 17
Norwalk 17
Salvador 17
Boston 16
Phoenix 16
Quito 16
Ankara 15
Bremen 15
Campinas 15
Ribeirão Preto 15
Scarsdale 15
Shenzhen 15
Brno 14
Hangzhou 14
Taizhou 14
Amsterdam 13
Totale 15.602
Salva come PNG Salva come JPEG
Nome #
PARAGANGLIOMA MALIGNO DEL CORPO CAROTIDEO.Rilievi Clinici, Morfologici, Istochimici E Ultrastrutturali Su Un Caso. 427
Amplification and overexpression of the PSMB5 gene contributes to bortezomib resistance in retreatment of patients with multiple myeloma. 236
Annual increase in the frequency of papillary thyroid carcinoma as diagnosed by fine-needle aspiration at a cytology unit in Sicily. 231
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy 228
Mechanical dispersion and cardiotoxicity in patients who underwent chemotherapy for breast cancer: an echocardiographic study 226
Analysis of multilayer strain and myocardial work in patients undergoing chemotherapy treatment: a 12 months follow-up 225
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations 224
zd1839"iressa" in heavily pretreated patients with advaned/metastatic non-small cell lung cancer(NSCLC):assessment of tolerability and the clinical benefit 223
Bone and lymph node metastases from occult mammary carcinoma: a case report of carcinoma of unknown primary (CUP) Syndrome 220
Analisi dello stato di metilazione del promoter di O6-methylguanine DNA methyltransferase (MGMT) e TMS1/ASC nei gliomi cerebrali diffusi di basso grado: possibili implicazioni cliniche e prognostiche. 218
Su di un caso di pseudomyxoma peritonei con diffusione spontanea alla pleura. 214
Apelin beyond kidney failure and hyponatremia: a useful biomarker for cancer disease progression evaluation 212
Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardioprotection, Italian Society of Cardiology (SIC) 210
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy 203
Epirubucin (EPI) and Paclitaxel (TAX) in advanced breast cancer.a phase II studyi 202
Myocardial damage pattern in women with breast cancer who underwent chemotherapy: strain polar maps analysis 202
Liver dysfunction in hcv infected patients with CD20-Positive B-Cell Lymphoma undergoing rituximab combination chemotherapy 193
EML4-ALK fusion gene in lung adenocarcinoma: A retrospective analysis of the outcome of cisplatin plus pemetrexed treated patients. 193
Should the Use of Surveillance Imaging in Diffuse Large B-Cell Lymphoma Be Discontinued? 192
[Serum levels of copper and zinc in patients with lung cancer] 191
Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer 189
Liquid biopsy for lung cancer early detection 189
A study of endometrial adenocarcinoma treated with tamoxifen by scanning and transmission electron microscopy. 188
Alectinib: A selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer 188
A PHASE II STUDY (21 DAY REGIMEN) OF GEMCITABINE AND CISPLATIN IN TRANSITIONAL CELL CARCINOMA OF BLADDER 187
Increased annual frequency of Hashimoto's thyroiditis between years 1988 and 2007 at a cytological unit of Sicily. 187
Left atrial function in patients undergoing chemotherapy: additional value of 2D longitudinal strain 187
An acute-leukaemia-like picture due to breast carcinoma cells. 186
Applications of genomics in NSCLC 185
[(186)Re]HEDP in the palliation of painful bone metastases from cancers otherthan prostate and breast. 183
ANALYSES AND DETERMINATION OF LONIDAMINE RELEASE FROM PHARMACEUTICAL FORMULATION. 183
A randomized factorial trial of sequential doxrubicina and CMF vs CMF and chemoterapy alone vs chemoterapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer 183
Gemcitabine (GEM) and cisplatin (CIS) in advanced/metastatic transitional cell carcinoma (TCC) of bladder:phase II study 183
Endocrine toxicity of immune checkpoint inhibitors (anti-PD-1/PD-L1) in advanced cancer 182
Evaluation of quality of life of patients submitted to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis of gastrointestinal and ovarian origin and identification of factors influencing outcome. 181
Cancer screening in HIV-infected patients: early diagnosis in a high-risk population 180
ANALYSES AND DETERMINATION OF LONIDAMINE RELEASE FROM PHARMACEUTICAL FORMULATION. 177
Amplification and overexpression of the PSMB5 gene contribute to Bortezomib resistance in re-treatment of patients with Multiple Myeloma 176
A novel HPLC method for the determination of mitoxantrone in pharmaceutical formulations. 174
Early assessment of chemotherapy-related cardiovascular toxicity in patients with breast cancer 174
Bleomycin, epirubicin, carboplatin (BECA) in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck 171
A PHASE III RANDOMIZED TRIAL COMPARING THREE PLATINUM-BASED DOUBLETS IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): IMPACT OF PS=2 VS 0 OR 1 AND AGE ³70 VS <70 ON CHEMOTHERAPY OUTCOME 170
Razionale e tecniche della chirurgia citoriduttiva e della chemioipertermia peritoneale. 170
The treatment of peritoneal carcinomatosis in elderly patients. 170
A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin 167
Espressione differenziale di un panel di miRNA in tumori cerebrali astrogliali con diverso grado di malignità. 167
Analytical profile and release of lonidamine from pharmaceutical formulation 166
Gemcitabine (GEM) and cisplatin (Cis) in advanced/metastatic transitional cell carcinoma (TCC) of bladder: Phase II study 166
Myelodysplastic syndrome appearing during imatinib mesylate therapy in a patient with GIST 165
90Y-IBRITUMOMAB TIUXETAN CONSOLIDATION AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IMPROVES SURVIVAL OF INTERMEDIATE/HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS NOT RESPONDING ADEQUATELY TO FIRST 165
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: a phase II study. J Chemother. 1999 Feb;11(1):74-7. PMID: 10078785 [PubMed - indexed for MEDLINE] 165
Antiblastic treatment of advanced cervical carcinoma and its recurrences: assessment of four different polychemotherapies used for a decade. 164
HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy. 164
Unusual relapse of hepatocellular carcinoma 164
Thyroid hormone autoantibodies: Are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments? 164
VP16, epirubicin and procarbazine in the treatment of advanced non-small-cell lung cancer. 162
Psycho-Neuro-Endocrine-Immune System (PNEI) Involvement as Prognostic Marker in Breast Cancer Patients at 10 Years of Follow Up 161
Author Correction to: Prevalence of Use and Cost of Biological Drugs for Cancer Treatment: A 5-Year Picture from Southern Italy 159
ZD 1839 IRESSA IN HEAVILY PRETREATED PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER:ASSESSMENT OF TOLERABILITY AND CLINICAL BENEFIT 157
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: A phase II study 156
Risk of occult hepatitis B virus infection reactivation in patients with solid tumours undergoing chemotherapy 155
Surgical treatment for congestive heart failure with autologous adult stem cell transplantation 153
Targeted drugs in small-cell lung cancer 153
Association between XPD 312 single nucleotide polymorphism (SNP) and clinical outcome in stage IIIA-B non-small-cell lung cancer (NSCLC) patients (P) < 59 years (Y) treated with chemotherapy followed by surgery 153
Peritoneal carcinomatosis of colorectal origin. 152
La farmacogenomica nei tumori del polmone 151
Severe pulmonary complications after bortezomib treatment for multiple myeloma: An unrecognized pulmonary vasculitis? 150
Trattamento palliativo dei tumori del retto-sigma mediante elettrocoagulazione endoscopica.” 150
Sternal metastasis as initial presentation of a unknown rectal cancer 149
First Line Chemotherapy with Oral Vinorelbine (oV) in Elderly Hormone-Refractory Prostate Cancer (HRPC) Patients (pts 148
Clodronate and radiotherapy for the treatment of osteolysis caused by metastasis of breast carcinoma and non-small cell lung carcinoma. A retrospective study 146
Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases 145
Treatment of advanced and/or metastatic epidermoid carcinoma of the head and neck: an effective combination chemotherapy with bleomycin, methotrexate and ftorafur. 144
Gemcitabine combined with Oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma 144
Relapsed or refractory extranodal DLBCL treated with lenalidomide: A single center study 144
Thyroid function, autoimmunity and nodules in hematological malignancies 144
Extramedullary plasmacytoma presented as a non-functional invasive pituitary macro-adenoma. 143
SUBCUTANEOUS LOW-DOSE ALEMTUZUMAB AS FIRST LINE THERAPY FOR ELDERLY CLL PATIENTS WITH DELETION OF 17p 141
A PHASE II STUDY (21 day regimen) OF GEMCITABINE (Gem) AND CISPLATIN ( Cis) IN ADVANCED/METASTATIC TRANSITIONAL CELL CARCINOMA (TTC) OF BLADDER 141
Retrospective analiysis of P-STAT6 expression as predictive marker in primary nervous system lymphoma patients assigned to high-dose methotrexate 141
Salvage therapy for primary central nervous system lymphoma with Y-90-Ibritumomab and Temozolomide 141
Transpersonal Therapy Combined with Best Supportive Care In Hospice Improve Patient’s Quality of Life and Quality Of Death 141
Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study. 140
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients 140
Studio anatomo-clinico di due casi di sarcoma sinoviale monofasico del ginocchio 139
Beyond global longitudinal strain: early impairment of apical function after antracyclines therapy 136
Temozolomide-induced shrinkage of a pituitary carcinoma. 136
Use of bisphosphonates in oncology 136
How cells respond to interferons. 134
Serum levels of copper and zinc in patients with lung cancer 133
ERLOTINIB IN A PATIENT WITH ACUTE MYELOGENOUS LEUKEMIA AND CONCOMITANT NON-SMALL-CELL LUNG CANCER 132
Imatinib-induced apoptosis in the eosinophils of patients with a hypereosinophilic syndrome: A surrogate marker of response? 132
MYELODYSPLASTIC SYNDROMES DEVELOPING DURING IMATINIB THERAPY FOR GIST 132
Behavior of serum sialic acid levels at various stages of neoplastic disease 131
Efficacy and toxicity of weekly Docetaxel as second/third line chemotherapy for advanced Non Small Cell lung cancer (NSCLC) 129
DASATINIB INDUCES A RESPONSE IN CHRONIC LYMPHOCYTIC LEUKEMIA 128
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS). 128
Gemcitabine as single agent in the treatment of elderly patients with advanced non small cell lung cancer 125
VP16, epirubicin and procarbazine in the treatment of advanced non-small-cell lung cancer. 124
The treatment of recurrent and metastatic cervical carcinoma. Evaluation of an antiblastic combination of methotrexate-adriamycin-bleomycin (MAB) 123
Totale 17.032
Salva come PNG Salva come JPEG
Categoria #
all - tutte 88.002
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 88.002
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202167 0 0 0 0 0 0 0 0 0 0 0 67
2021/20221.548 10 224 45 40 58 20 84 60 31 244 269 463
2022/20233.895 309 370 174 284 303 396 57 235 1.601 22 95 49
2023/2024988 73 128 66 114 73 258 23 45 3 79 26 100
2024/20254.298 57 38 74 252 221 134 75 1.015 1.146 250 337 699
2025/202611.964 617 662 1.003 691 969 2.672 1.495 1.488 1.493 476 221 177
Totale 27.605